skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Imaging and dosimetric characteristics of 67 Cu

Journal Article · · Physics in Medicine and Biology
ORCiD logo [1]; ORCiD logo [2];  [1];  [2];  [2];  [2];  [1];  [1]; ORCiD logo [1]
  1. Univ. of Iowa, Iowa City, IA (United States)
  2. Argonne National Lab. (ANL), Lemont, IL (United States)
+ Show Author Affiliations

In recent years the use of beta-emitting radiopharmaceuticals for cancer therapy has expanded rapidly following development of therapeutics for neuroendocrine tumors, prostate cancer, and other oncologic malignancies. One emerging beta-emitting radioisotope of interest for therapy is 67Cu (t1/2: 2.6 d) due to its chemical equivalency with the widely-established positron-emitting isotope 64Cu (t1/2: 12.7 h). Here we evaluate both the imaging and dosimetric characteristics of 67Cu, as well as producing the first report of SPECT/CT imaging using 67Cu. To this end, 67Cu was produced by photon-induced reactions on isotopically-enriched 68Zn at the Low-Energy Accelerator Facility (LEAF) of Argonne National Laboratory, followed by bulk separation of metallic 68Zn by sublimation and radiochemical purification by column chromatography. Gamma spectrometry was performed by efficiency-calibrated high-purity germanium (HPGe) analysis to verify absolute activity calibration and establish radionuclidic purity. Absolute activity measurements corroborated manufacturer-recommended dose-calibrator settings and no radionuclidic impurities were observed. Using the Clinical Trials Network anthropomorphic chest phantom, SPECT/CT images were acquired. Medium Energy (ME) SPECT collimation was found to provide the best image quality from the primary 185 keV gamma emission of 67Cu. Reconstructed images of 67Cu were similar in quality to images acquired using 177Lu. Recovery coefficients were calculated and compared against quantitative images of 99mTc, 177Lu, and 64Cu within the same anthropomorphic chest phantom. Production and clinical imaging of 67Cu appears feasible, and future studies investigating the therapeutic efficacy of 67Cu-based radiopharmaceuticals are warranted.

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE Office of Science (SC), Engineering & Technology. Office of Isotope R&D and Production
Grant/Contract Number:
AC02-06CH11357
OSTI ID:
1774100
Journal Information:
Physics in Medicine and Biology, Vol. 66, Issue 3; ISSN 0031-9155
Publisher:
IOP PublishingCopyright Statement
Country of Publication:
United States
Language:
English

References (20)

Gamma spectrum analysis including NAA with SAMPO for windows journal May 1995
MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy journal June 2012
Neuroendocrine Tumor Therapy: 177 Lu-DOTATATE journal August 2018
Copper-67 production on electron linacs—Photonuclear technology development
  • Ehst, D. A.; Smith, N. A.; Bowers, D. L.
  • 14TH INTERNATIONAL WORKSHOP ON TARGETRY AND TARGET CHEMISTRY, AIP Conference Proceedings https://doi.org/10.1063/1.4773959
conference January 2012
Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent journal July 1985
In Vivo Transchelation of Copper-64 from TETA-Octreotide to Superoxide Dismutase in Rat Liver journal July 2000
Peptide receptor radionuclide therapy journal March 2007
The production of copper 67 from natural zinc using a linear accelerator journal November 1970
Nuclear Data Sheets for A = 67 journal October 2005
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy journal October 2015
177 Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer journal May 2020
In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. a new somatostatin analog with improved target tissue uptake journal April 1999
In Vivo Instability of 177 Lu-DOTATATE During Peptide Receptor Radionuclide Therapy journal January 2020
Dose point kernels for 2,174 radionuclides journal September 2019
Comparison of Four 64 Cu-Labeled Somatostatin Analogues in Vitro and in a Tumor-Bearing Rat Model:  Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted Radiotherapy ‖ journal April 1999
Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research journal August 2009
A new separation procedure for 67Cu from proton irradiated Zn
  • Dasgupta, A. K.; Mausner, L. F.; Srivastava, S. C.
  • International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, Vol. 42, Issue 4 https://doi.org/10.1016/0883-2889(91)90140-V
journal January 1991
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours journal April 2019
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues journal December 2005
Development of a simple and selective separation of 67Cu from irradiated zinc for use in antibody labelling: A comparison of methods journal May 1995

Similar Records

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
radiopharmaceutical therapy
theranostics
copper
SPECT/CT